Nearly 10,000 heart attack patients to test ancient pill for better recovery

NCT ID NCT07153744

Not yet recruiting Disease control Sponsor: Shanghai Hutchison Pharmaceuticals Limited Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 26, 2026 · Updated 1 time

Summary

This large study will test whether adding Shexiang Baoxin Pill (Muskardia) to standard treatment helps people who have had a heart attack. About 9,588 participants will receive either standard care alone or standard care plus the pill for 12 months. The goal is to see if the pill lowers the chance of further heart problems, stroke, or death.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Shexiang Baoxin Pill (Muskardia)
What this could lead to: If it works, this could provide a new add-on treatment to reduce the risk of further heart problems and improve recovery after a heart attack.
What could go wrong: This is a phase 4 real-world study, so it builds on existing knowledge rather than testing a brand-new approach. The pill may not significantly lower complication rates beyond standard care, and individual results may vary.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ACUTE MYOCARDIAL INFARCTION (AMI) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

acute myocardial infarction

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ACUTE MYOCARDIAL INFARCTION (AMI) PERCUTANEOUS CORONARY INTERVENTION (PCI)

Contacts and locations

Locations

Zhongshan Hospital, Fudan University

Shanghai, 200032, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.